We Don’t Just Consume Marijuana


Whenever I write anything about the solutions to the opioid epidemic, there’s a question I almost always get from readers: What about medical marijuana?

The question comes in reference to a growing body of research — which I’ve written about before — indicating that the legalization of medical marijuana may lead to a drop in drug overdose deaths. The idea: Marijuana is an effective painkiller, so it could be a substitute for some opioid painkillers that have led to the current overdose epidemic. Because marijuana doesn’t cause deadly overdoses and is less addictive than opioids, replacing some use of opioids with pot could prevent some overdose deaths.

There’s some evidence for medical marijuana reducing opioid deaths

There have been some studies suggesting that medical marijuana could help reduce opioid overdose deaths.

For one, the best review of the research to date about marijuana’s health effects, from the National Academies of Sciences, Engineering, and Medicine, found that there’s “conclusive evidence” for marijuana as a treatment for chronic pain. At the same time, there’s evidence questioning whether opioids really are more effective at treating chronic pain compared to alternative treatments, suggesting that there’s a lot of room to substitute marijuana, at least for some patients.

One potential wrinkle: We already have a lot of non-opioid pain treatments. As Stanford University pain specialist Sean Mackey previously said, there are 200-plus non-opioid pain medications, not to mention nonpharmacological approaches. So marijuana isn’t providing something entirely new here if it’s used for pain treatment. Other studies have produced similar results too, so this isn’t just one outlier study.

We have much better evidence for other policies

While the evidence for medical marijuana isn’t definitive, there is much, much stronger evidence for other interventions in the opioid crisis.

There are anti-addiction medications like buprenorphine and methadone. Studies show that these medications reduce the all-cause mortality rate among opioid addiction patients by half or more and do a far better job of keeping people in treatment than nonmedication approaches. In France, the government expanded doctors’ ability to prescribe buprenorphine in 1995 to confront an opioid epidemic — and overdose deaths declined by 79 percent from 1995 to 1999, according to a 2004 study published in the American Journal on Addictions.

But access to these medications — and treatment in general — is bad. According to a 2016 report by the surgeon general, only 10 percent of people in the US with a drug use disorder get specialty treatment. One reason for that low rate is a lack of supply to meet demand: The White House’s opioid commission, for example, found that 85 percent of US counties have no specialty opioid treatment programs that provide medications for opioid addiction.

An evidence-based approach to tackle the opioid crisis would significantly boost access to treatment. Experts estimate that achieving this could cost tens of billions of dollars a year over several years. But Congress has only appropriated limited-time funding boosts here and there to address the crisis — none of which add up to the tens of billions or anything close to that amount

This is only the tip of the iceberg. As I explained before, experts have many more evidence-based ideas for addressing the opioid epidemic. The problem is the political and legislative response in actually implementing these ideas has long lagged behind the science — so the opioid crisis continues, killing tens of thousands every year.

Again, it’s not that medical marijuana couldn’t help address the epidemic. The evidence does suggest, to me, that it could. But if we have ideas with more evidence behind them, maybe we should try those first before getting too caught up in a scheme with much weaker evidence behind it.

Get Your Best Strains and Live Healthy


Medical cannabis has been legislated in several US states since the 1990s. In California,  the so-called Compassionate Use Act, is approved by state voters in the November 1996 elections, endorsing legalization. medical cannabis the next day. The new California law, the first of its kind in the United States, decriminalizes the possession, use and cultivation of cannabis for patients with a “written or oral” recommendation from their doctor.

Most Suitable.

Among the conditions deemed eligible by law are listed arthritis, cachexia, cancer, chronic pain, HIV or AIDS, epilepsy, migraines and multiple sclerosis. The law does not specify a limit on the quantities that eligible patients can own or cultivate. California law is in direct conflict with national narcotics legislation, and in January 1998, the federal government sued the Oakland Cannabis Buyers Cooperative (OCBC), calling for a ban on the distribution of cannabis in the United States. patients. The district court makes a judgment in favor of the federal government, and the OCBC is temporarily closed.


International Association for Cannabis Medical [archive] – Scientific Association of Patients, Doctors and Experts based in Germany.
Frequently asked questions about marihuana for medical purposes [archive], on the Health Canada website [archive]
UFCMED [archive] Francophone Union for Cannabinoids in Medicine
Active Principles [archive] – French Association of Patients Using Cannabis.
National Organization for the Reform of Marijuana Laws [archive], a non-profit American organization advocating the legalization of cannabis.
(BMC [archive], Bureau voor Midicinale Cannabis, Office of Medicinal Cannabis, Ministry of Health of the Netherlands.
Legal Situations in Europe and the United States / IACM [archive]

The Greenherbs Revolution


Presumed therapeutic applications are listed by the International Association for Medical Cannabis including: nausea and vomiting, anorexia and cachexia, spasms, movement disorders, pain, glaucoma, epilepsy, asthma, addiction and withdrawal, psychiatric symptoms, depression, autoimmune diseases and inflammations; and various syndromes.

Scientific efforts in this area are constantly progressing, as evidenced by the considerable evolution of the number of studies carried out in recent years. In the last decade, this number has more than doubled, bringing the total number of publications to more than 15,000 in 2016.

Why Greenherbs.

The following properties have been scientifically studied and have been the subject of publications whose conclusions are controversial:
Analgesics: terminally ill and for chronic pain resistant to traditional treatments;
Relaxants and sleeping pills: terminally ill, sleep disorders;
Anti-spasmodic: multiple sclerosis, epilepsy;: multiple sclerosis, epilepsy;
Anti-emetic: treatment of side effects of chemotherapy or other heavy treatments;
stimulating the appetite and restoring the desire to eat: fight against cachexia (extreme thinness) and promotes weight gain;
Broncho-dilators: asthma;
Anti-inflammatory: the non-psychoactive cannabidiol CBD (see Cannabinoid) is known for its affinities with CB2 receptors located on T immune cells.
Vasodilators: glaucoma, migraines;


  1. why do people consume marijuana
  2. why are there a variety of marijuana strains
  3. are they really helpful as medications
  4. have they been medically tested